Background: Well-known fact is that the good surgical treatment, leaving only small residuals of thyroid tissue, is the outmost valid predictive factor of successful ablative radioiodine treatment. Assuming that all patients had state of the art surgical treatment, with this study we tried to evaluate other possible predictive factors of successful radioiodine therapy after total thyroidectomy. Methods: Total of 56 patients (15 males and 41 females mean age 43.37±13), operated during the year 2001 was evaluated. Due to differentiated carcinoma of the thyroid total thyreoidectomy was done in 7 with follicular and in 49 patients with papillary cancer. Forty-one patients received ablative 131 I dose (3.7GBq) and fifteen patients received therapeutic dose (5.55GBq) of radioiodine therapy. As possible predictive factors the TNM classification (T1, 6; T2, 17; T3, 4; T4, 28 and 24 with N0 and 32 with N1), the number of foci on whole body scan (WBS), and the serum level of thyroglobulin were statistically evaluated. One year after radioiodine therapy control WBS was done and successful outcome of the therapy was considered to be the WBS without visible accumulation of radioiodine and with low serum level of thyroglobulin. Results: Outcome of ablative radioiodine therapy was considered as successful in 55.4% patients and 44.6% of patients needed additional radioiodine therapies. Only the number of foci and the level of thyroglobulin showed statistically significant (p(0.05) influence on the outcome of applied radioiodine therapy. Conclusion: Significant influence of the thyroglobulin level and number of foci on the WBS in patients with total thyroidectomy could be explained by the fact that there were the signs of minimum thyroid residual tissue, and that there were no microscopic spread of disease
Background: Aim of the study was to determine the frequency of regional nodal metastases (N1) of differentiated thyroid carcinomas (DTC), to analyze the modes of treatment, course of disease, and outcome. Methods: In Department of Nuclear Medicine in Sremska Kamenica, 363 DTC patients were treated from 1977 to the end of 2000. Nodal metastases had 182 patients most of them were followed to the end of 2000. Methods: All patients with N1 were treated surgically (operation of thyroid gland was done in all patients, surgical treatment of lymph nodes in 80.2% of them), afterwards by radioiodine and long-life by hormonal therapy; external beam therapy was applied in 9.9% of patients, chemotherapy in 1.6% of patients. The range of follow-up was from 2 months to 24.2 years, the mean 4.7 years. Results Nodal metastases were detected first, before primary tumor, in 21.9% patients, and simultaneously in 63.2% patients. They appeared subsequently after detection and initial treatment of primary tumor in 14.8% patients the incomplete initial therapy in this subgroup of patients was more frequent than complete therapy (p<0.01). Regional metastases N1b were present more frequently than N1a (p<0.001). Distant metastases (M1) in N1 group were discovered in 27.5% of patients; they were more frequent than in N0 group of patients (p<0.001). Nodal metastases were found more frequently in the group of papillary than in the group of follicular carcinoma (p<0.001), and in the men than in the women with DTC (p<0.001). Remission was achieved in 67.7% of patients with N1. Disease related deaths occurred in 15.8% of patients with N1; M1 was cause of deaths in 10.2% of patients locoregional disease (T4 and/or N1) in 5.9% of patients, and M1+extended T4 and/or N1 in 0.7% of patients. Late complications of treatment caused the death in 2.1% of patients with N1. The relapses of disease occurred in 31.9% of patients. The survival probability after onset of the nodal disease in N1M0 subgroup was 0.88+/-0.05 after 10 years, and 0.64+/-0.16 after 20 years; the probability of survival was very significantly shorter when M1 were present (p<0.001). Conclusion: Regional metastases were detected in the half of DTC patients. The detection of N1 was the first indicator of thyroid tumor in about 20% of them. Nodal metastases grew later on after detection and initial treatment of primary tumor in about 15% of patients, mostly as a result of inadequate treatment. The frequency of N1 was greater in patients with papillary type of tumor and in males. The presence of M1 had significant influence on survival of patients with N1
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.